Waiting time for patients with history of malignant disease before listing for organ transplantation

Transplantation

Volumn 80, Issue SUPPL. 1, 2005, Pages

  Girndt, Matthias ^a   Köhler, Hans ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Immunosuppressive agents; Neoplasms; Transplant recipient; Waiting list

Indexed keywords

CYCLOSPORIN A; RAPAMYCIN;

AGE; ANAMNESIS; CANCER REGISTRY; CANCER REGRESSION; CANCER RELAPSE; CONFERENCE PAPER; EVIDENCE BASED MEDICINE; HOSPITAL ADMISSION; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL DECISION MAKING; NEOPLASM; NONHUMAN; ORGAN TRANSPLANTATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RECIPIENT;

CELL DIVISION; HUMANS; IMMUNOSUPPRESSION; NEOPLASMS; ORGAN TRANSPLANTATION; PROGNOSIS; TIME FACTORS; WAITING LISTS;

EID: 27644450875     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000187112.81714.26     Document Type: Conference Paper

References (22)

1. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf 2000; 23: 101.
2. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222.
3. Frezza EE, Fung JJ, van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 1997; 44: 1172.
4. Morath C, Mueller M, Goldschmidt H, et al. Malignancy in renal transplantation. J Am Soc Nephrol 2004; 15: 1582.
5. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001; 2: 293.
6. Koehl GE, Andrassy J, Guba M, et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004; 77: 1319.
7. Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003; 63: 917.
8. Margarit C, Charco R, Hidalgo E, et al. Liver transplantation for malignant diseases: selection and pattern of recurrence. World J Surg 2002; 26: 257.
9. Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004; 77: 1777.
10. Farag SS, VanDeusen JB, Fehniger TA, Caligiuri MA. Biology and clinical impact of human natural killer cells. Int J Hematol 2003; 78: 7.
11. Petersson E, Qi Z, Ekberg H, et al. Activation of alloreactive natural killer cells is resistant to cyclosporine. Transplantation 1997; 63: 1138.
12. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004; 77: 760.
13. Kasiske BL, Cangro CB, Hariharan S, et al. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2002; 1 Suppl 2: 1.
14. The EBPG Expert Group on Haemodialysis. European Best Practice Guidelines for Renal Transplantation (part 1). Nephrol Dial Transplant 2000; 15 Suppl 7: 1.
15. Kelly DM, Emre S, Guy SR, et al. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. Cancer 1998; 83: 1237.
16. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation 1993; 55: 742.
17. Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant 1997; 2: 14.
18. Meier-Kriesche HU, Ojo AO, Port FK, et al. Survival improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol 2001; 12: 1293.
19. Herzog CA, Ma JZ, Collins AJ. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 2002; 106: 2207.
20. Kliem V, Kolditz M, Behrend M, et al. Risk of renal cell carcinoma after kidney transplantation. Clin Transplant 1997; 11: 255.
21. Khauli RB. Genitourinary malignancies in organ transplant recipients. Semin Urol 1994; 12: 224.
22. Trofe J, Buell JF, Woodle ES, et al. Recurrence risk after organ transplantation in patients with a history of Hodgkin disease or non-Hodgkin lymphoma. Transplantation 2004; 78: 972.